Synairgen (LON:SNG) Shares Down 16% – Time to Sell?

Posted by Lauren Steadman on Mar 17th, 2025

Synairgen plc (LON:SNG – Get Free Report)’s share price fell 16% during trading on Monday . The company traded as low as GBX 0.73 ($0.01) and last traded at GBX 0.79 ($0.01). 920,817 shares traded hands during trading, a decline of 37% from the average session volume of 1,456,314 shares. The stock had previously closed at GBX 0.93 ($0.01).

Synairgen Trading Down 16.0 %

The stock has a 50 day simple moving average of GBX 1.97 and a 200 day simple moving average of GBX 3.29. The stock has a market cap of £7.68 million, a P/E ratio of -0.47 and a beta of -2.23.

Synairgen Company Profile

(Get Free Report)

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).